Table 3. Summary of major efficacy variables at the study end pointa.

	Placebo (N = 351)				10 mg Tadalafil (N = 185)				20 mg Tadalafil (N = 510)
	n	Baseline	End point	Change	n	Baseline	End point	Change	n	Baseline	End point	Change
IIEF-EF domain (mean)	347	14.6	16.7	2.0	181	13.9	21.9	7.2*	502	14.9	23.0	8.3*
Mean per-patient 'yes' response to SEP questions (%)
SEP2. Successful penetration	348	51.3	55.3	4.0	181	43.6	77.3	26.0*	502	54.2	82.9	31.5*
SEP3. Successful intercourse	348	20.7	33.4	13.8	181	15.4	64.1	44.5*	502	20.4	70.5	50.9*
GAQ question (%)
Improved erections	338		43.5		179		85.5*		493		85.4*
IIEF-EF ≥ 26 at end point, n (%)	336		40 (11.9)		175		63 (36.0)		489		222 (45.4)*
IEF domains (mean)
Intercourse satisfaction	347	6.2	8.0	1.7	181	5.9	10.2	3.9*	502	6.6	10.5	4.2*
Overall satisfaction	347	4.3	5.1	0.8	181	4.4	6.6	2.3*	502	4.4	6.8	2.5*

Abbreviations: GAQ, Global Assessment Question; IIEF, International Index of Erectile Function; N, number of patients randomized per treatment group; n, number of patients having both baseline and end point data; SEP, Sexual Encounter Profile.

^aLeast squares mean end point and change reported, with the exception of GAQ and return to normal erectile function (IIEF-EF ≥ 26) results.

^*P < 0.001 vs. placebo.